MX2018009218A - Anticuerpos de cgrp y sus usos. - Google Patents

Anticuerpos de cgrp y sus usos.

Info

Publication number
MX2018009218A
MX2018009218A MX2018009218A MX2018009218A MX2018009218A MX 2018009218 A MX2018009218 A MX 2018009218A MX 2018009218 A MX2018009218 A MX 2018009218A MX 2018009218 A MX2018009218 A MX 2018009218A MX 2018009218 A MX2018009218 A MX 2018009218A
Authority
MX
Mexico
Prior art keywords
cgrp
cgrp antibodies
antibodies
human
kits
Prior art date
Application number
MX2018009218A
Other languages
English (en)
Inventor
Allan Barrett
Chai Xiyun
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2018009218A publication Critical patent/MX2018009218A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/585—Calcitonins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2842—Pain, e.g. neuropathic pain, psychogenic pain

Abstract

La presente invención se relaciona con anticuerpos que se unen a CGRP humano, composiciones y kits que comprenden tales anticuerpos CGRP y métodos para usar tales anticuerpos CGRP para la detección de CGRP humano.
MX2018009218A 2016-01-28 2017-01-20 Anticuerpos de cgrp y sus usos. MX2018009218A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662288045P 2016-01-28 2016-01-28
PCT/US2017/014325 WO2017132062A1 (en) 2016-01-28 2017-01-20 Cgrp antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2018009218A true MX2018009218A (es) 2018-11-09

Family

ID=57910192

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009218A MX2018009218A (es) 2016-01-28 2017-01-20 Anticuerpos de cgrp y sus usos.

Country Status (11)

Country Link
US (1) US20190031748A1 (es)
EP (1) EP3408290A1 (es)
JP (1) JP2019501152A (es)
KR (1) KR20180091930A (es)
CN (1) CN108473567A (es)
AU (1) AU2017211043A1 (es)
BR (1) BR112018010596A2 (es)
CA (1) CA3007018A1 (es)
EA (1) EA201891196A1 (es)
MX (1) MX2018009218A (es)
WO (1) WO2017132062A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020239014A1 (zh) * 2019-05-30 2020-12-03 山东博安生物技术有限公司 抗cgrp抗体及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY153249A (en) * 2005-11-14 2015-01-29 Rinat Neuroscience Corp Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
WO2007076336A1 (en) * 2005-12-22 2007-07-05 Eli Lilly And Company Treatment of migraine with anti-cgrp antibodies
NZ587292A (en) * 2008-03-04 2012-09-28 Pfizer Ltd Use of anti-CGRP (calcitonin gene-related peptide) antagonists to treat chronic pain
CA2716799C (en) 2008-03-04 2018-05-22 Pfizer Limited Methods of treating inflammatory pain
JO3330B1 (ar) * 2010-06-10 2019-03-13 Lilly Co Eli الأجسام المضادة cgrp
US9745373B2 (en) * 2011-05-20 2017-08-29 Alderbio Holdings Llc Anti-CGRP compositions and use thereof

Also Published As

Publication number Publication date
CA3007018A1 (en) 2017-08-03
AU2017211043A1 (en) 2018-06-14
EP3408290A1 (en) 2018-12-05
KR20180091930A (ko) 2018-08-16
JP2019501152A (ja) 2019-01-17
US20190031748A1 (en) 2019-01-31
WO2017132062A1 (en) 2017-08-03
EA201891196A1 (ru) 2018-12-28
BR112018010596A2 (pt) 2018-11-13
CN108473567A (zh) 2018-08-31

Similar Documents

Publication Publication Date Title
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
PH12019500540A1 (en) Anti-pd-1 antibodies and their uses
MX2018008369A (es) Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
MX2022005173A (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos.
PH12021550337A1 (en) Anti-gdf15 antibodies, compositions and methods of use
TR201901445T4 (tr) Il2rbeta/yaygın gamma zinciri antikorları.
PH12019501357A1 (en) Anti-ox40 antibodies and their uses
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
NZ738008A (en) Tigit-binding agents and uses thereof
MX2017003478A (es) Anticuerpos anti-fgfr2/3 y metodos para su uso.
SG10201901057UA (en) Anti-pd-l1 antibodies
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
MX2017016169A (es) Anticuerpos anti-her2 y metodos de uso.
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
PH12016501366A1 (en) Novel anti-baff antibodies
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
MX2020010951A (es) Anticuerpos anti-hla-g y utilizacion de los mismos.
WO2018119425A3 (en) Anti-lilrb3 antibodies and methods of use thereof
EA201891527A1 (ru) Композиции и способы обнаружения и лечения рака пищевода
SA518391028B1 (ar) Cd37 أجسام مضادة واختبارات للكشف عن
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка
EA201992315A1 (ru) Композиции и способы для лечения рака легкого
PH12019502694A1 (en) Anti-trkb antibodies
MX2018004986A (es) Anticuerpos monoclonales anti-chinches y metodos de elaboracion y usos de los mismos.